Hodgkin’s Lymphoma Treatment Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2019 – 2027

Lymphoma is a cancer caused in lymphocytes of the body, i.e. white blood cells. It is of two types – Hodgkin’s Lymphoma and Non-Hodgkin’s Lymphoma. Hodgkin’s Lymphoma can be characterized into two categories – classic and nodular lymphocyte predominant. Some of the signs indicating presence of Hodgkin’s Lymphoma in the body is fever, sudden weight loss, and swollen lymph nodes. Hodgkin’s Lymphoma is mostly treated with chemotherapy alone or with the combination of radiotherapy.

Request Sample Copy of Research Report @ http://bit.ly/30SYZhP

Global Hodgkin’s Lymphoma Treatment Market Drivers

Approvals of the drugs by regulatory bodies for the treatment of Hodgkin’s lymphoma is expected to drive the global Hodgkin’s lymphoma market growth. In 2018, Seattle Genetics, Inc. received the Health Canada approval for its supplemental New Drug Submission that expands the use of Adcetris (brentuximab vedotin) in combination with AVD (Adriamycin, vinblastine and dacarbazine) chemotherapy in patients with previously untreated Stage IV Hodgkin lymphoma (HL). Adcetris is indicated for the treatment of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine.

Furthermore, key players are constantly trying to expand the indications of their already approved drug. For instance, in March 2017, Merck & Co. Inc. received an approval by U.S. Food & Drug Administration (FDA) of the drug, Keytruda for the treatment of classical Hodgkin’s lymphoma. It is approved on the basis of response durability and tumor response rate and is supposed to be administered intravenously into patients. It was originally approved in 2014. Such frequent approvals of drugs by regulatory bodies are expected to impact positively on the global Hodgkin’s lymphoma treatment market growth.

Global Hodgkin’s Lymphoma Treatment Market Regional Analysis

North America is expected to hold a dominant position in the global Hodgkin’s lymphoma market over the forecast period. Frequent research and development activities done by the government and other organizations is expected to drive the North America Hodgkin’s lymphoma treatment market growth. For instance, in December 2016, Ohio State University Comprehensive Cancer Center and National Cancer Institute (NCI) commenced a U.S. FDA clinical trial of Ibrutinib in combination with Nivolumab, in the patients suffering from classical Hodgkin’s Lymphoma, in the U.S to study its efficacy. Ibritunib may block the cancer cell growth by blocking the enzymes responsible for growth and Nivolumab may block cancer cells by targeting different cells. Currently, it’s in the second phase of clinical trials. The study involves 17 participants and is estimated to be completed by 2020.

Furthermore, various outside organizations are involved in research and development activities for development and gaining the U.S. FDA approval of novel Hodgkin’s lymphoma treatment drug in the U.S.

Request For Customization of Research Report @ http://bit.ly/2Keuc9h

For instance, in September 2017, Chinese PLA General Hospital, a Chinese government organization, commenced its clinical trial of Decitabine in combination with SHR – 1210. It is being used for the treatment of Hodgkin’s lymphoma. SHR – 1210 is a monoclonal antibody, while Decitabine is an investigational drug, which is capable of boosting antigen expression. The clinical study is for analyzing the safety and efficacy of the drugs. Currently, it is in the second phase of clinical trials.

Global Hodgkin’s Lymphoma Treatment Market Restraints

Side effects related with drugs used for the treatment of Hodgkin’s lymphoma is expected to adversely affect adoption of these drugs, thereby hindering the global Hodgkin’s lymphoma treatment market growth. For instance, according to American Cancer Society, drugs used for treating Hodgkin’s lymphoma such as doxorubicin and bleomycin can damage heart and lungs respectively. Hence, such side effects of drugs can hinder the global Hodgkin’s lymphoma treatment market growth.

Global Hodgkin’s Lymphoma Treatment Market Key Players

Some of the major players operating in the global Hodgkin’s lymphoma treatment market include Emcure Pharmaceuticals Pvt. Ltd., Aspen Global Inc., Pfizer Inc., Ono Pharmaceuticals Co. Ltd., Corden Pharma Latina SPA, Horizon Pharma USA Inc., Cipla Ltd., Lediant Biosciences Inc., Jansenn Research and Development LLC, and Merck & Co., Inc.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Medical Vacuum System Market Will Grow With Advancement in Technology Near Future

Medical vacuum system is designed to remove unwanted fluids or gases from hospitals and laboratories. These systems are used in draining wounds, preparation of wound closures, lung drainage, and chest drainage. Medical vacuum system is considered as an essential part of healthcare facilities. There are various types of vacuum pumps such as dry claw vacuum system, oil-sealed liquid ring, and water sealed liquid ring. Suctioning is a critical part of patient care and life saving procedures, while vacuum system makes surgery faster and safer.

Download PDF Brochure Of This Research Report @ http://bit.ly/2KeU8BH

Medical Vacuum System Market Drivers

Key players in the market are focused on launching new products, which is expected to boost the medical vacuum system market growth. For instance, in January 2016, BeaconMedaes launched its new oil-less rotary vane vacuum system. It has new features such as touch screen control with an embedded web server and space saving design.

Furthermore, in September 2017, Edward launched its new air-cooled nXLi dry vacuum pump range, which is ideal for scientific instruments. It is an intelligent drive which enables system to achieve an enhanced performance from single phase power supply. This new vacuum pump is available in two types such as nXL110i and nXL200i and both are used in the Liquid Chromatography-Mass Spectrometry (LCMS) and Inductively Coupled Plasma Mass Spectrometry (ICPMS).

Medical Vacuum System Market Restraints

Product recall is a major restraining factor for growth of the medical vacuum system market. For instance, in September 2018, Vyaire Medical, Inc. received product recall alert from the U.S. Food and Drug Administration (FDA) for Tri-Flo Subglottic Suction System. The system was recalled due to the risk of device breakage during surgery, which may cause serious injury or death of patient.

Medical Vacuum System Market Regional Analysis

On the basis of region, the global medical vacuum system market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold dominant position in the global medical vacuum system market, owing to increasing approval activities from the U.S FDA. For instance, in August 2018, SOMAVAC Medical Solution Inc. received approval from the U.S. FDA for its wearable post-surgical pump SOMAVAC 100 sustained vacuum system. It is a closed suction drain device. This vacuum system applies sustained vacuum to closed wound surgery to remove fluid and reduce risk of seroma.

Furthermore, Asia Pacific is projected to witness significant growth in the global medical vacuum system market, owing to increasing launch of new medical vacuum systems. For instance, in December 2018, Ebara Corporation launched its new air-cooled dry vacuum pump model EV-PA, which creates a cleaner vacuum environment. It can be used for analytical instruments, medical equipment, and in the food and coating industries.

Ask For Discount Before Purchasing This Business Report @ http://bit.ly/2XhHqWC

Key players operating in the global medical vacuum system market include, Asahi Kasei ZOLL Medical Corporation, INTEGRA Holdings, Medela AG, Precision Medical, Inc., Dregerwerk, AG & Co KGaA, Allied Healthcare Products Inc. Gardner Denver Holdings, Busch Holdings GmbH, Laerdal Medical, and Air Techniques.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Infertility Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2019 – 2026

Infertility is a global health issue as its affects both men and women. Infertility in females occur due to increasing age, polycystic ovarian syndrome (PCOS), obesity, and multiple miscarriages whereas in males infertility occur due to erectile dysfunction, low sperm count, abnormal sperms, etc. Increasing prevalence of infertility is expected to propel demand for the infertility drugs. According to World Health Organization (WHO) 2012 report, infertility affects one out of four couples in emerging economies. Many researchers are working towards finding an efficient treatment for the infertility. For instance, in 2018 at Ben-Gurion University (BGU), Israel researchers were developing a new, single-dose infertility treatment based on a new compound. The new treatment, developed by the BGU researchers, stimulates the expression of the telomerase and re-elongates the telomeres, protecting the cells from damage.

Request Sample Copy of Research Report @ http://bit.ly/2W4lxIW

The global infertility drugs market size was valued at US$ 3.8 billion in 2017, and is expected to witness a CAGR of 5.8% over the forecast period (2019 – 2026).

Increasing Research & Development for More Effective Treatment with Lesser Side-Effects to Reduce Infertility is expected to Drive Growth of the Infertility Drugs Market  

The infertility drugs market size is expected to witness significant growth, owing to the rising research and developmental studies for more effective treatment to achieve pregnancy and live births. For instance, in 2014, a team of researchers at National Institutes of Health’s (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) found that women treated with Letrozole have high rates of ovulation and live births than women treated with the standard drug, Clomiphene. Furthermore, among women who received Letrozole, 27.5% of them eventually had a live birth and women who received clomiphene, only 19.1% them experienced a live birth. The cumulative ovulation rate was higher for the Letrozole group, with ovulation occurring 61.7% of the time, and the women in the clomiphene group ovulated 48.3% of the time.

Market Dynamics

Increasing prevalence of infertility in couples is highly contributing to infertility drugs market size. For instance, According to Centres for Disease Control and Prevention (CDC) report of 2018, about 6% of women aged 15 to 44 years in the U.S. were unable to get pregnant after one year of trying (infertility). Also, about 12% of women aged 15 to 44 years in the U.S. have difficulty getting pregnant or carrying a pregnancy to term. Infertility also affects rising number of men. According to the same source, almost 9% of men aged 25 to 44 years in the U.S. reported that they required medical help for reproduction.

Inquire Here Before Purchase of Research Report @ http://bit.ly/2Z1PvPH

Infertility Drugs Market - Competitive Landscape

Key players operating in the global infertility drugs market include Merck & Co., Ferring Pharmaceuticals, LIVZON Pharmaceutical Group Inc., Abbott Laboratories, Bayer AG, and Zydus Pharmaceuticals.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Hemodialysis Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2019 – 2027

Hemodialysis also termed as dialysis is a process of blood purification, when human kidney fails to do so (due to kidney failure or end-stage renal diseases). In end–stage renal diseases, toxic waste products, and extra fluids are built-up in the body. There is also imbalance of salts and minerals in the blood. A hemodialysis or kidney transplant is opted in such cases. A hemodialysis machine is used to perform hemodialysis. The Component present in a hemodialysis machine are – dialyzer, a dialysis solution (sterilized mineral ions), and tubes for passing of blood and dialysis solution. The blood flows through the tubes and enters into the machine, where the waste products are removed through the filter and the blood again is passed back to the body through the tubes.

Download PDF Brochure Of This Research Report @ http://bit.ly/2EGUBck

Global Hemodialysis Market Drivers

Strategies such as partnerships, collaborations, mergers, and acquisitions, adopted by the key players are expected to drive the global hemodialysis market growth. For instance, in July 2018, B. Braun Medical Inc., a medical device company acquired bloodline portfolio business of NxStage Medical Inc., a medical technology company for expansion of their dialysis product portfolio. B. Braun Medical Inc. is going to add “Streamline Express” (bloodline manufactured by NxStage Medical Corporation), a tubing set used in hemodialysis machine into their product portfolio.

Furthermore, in October 2018, Baxter Healthcare Corporation, a medical device company collaborated with Mayo Clinic, a non–profit medical center, for establishment of renal care center in Florida, U.S. The purpose of setting up the center is to serve patients with kidney failure and trial of new products, including hemodialysis machines. This may allow higher adoption of hemodialysis machines by the healthcare institutions, thereby expected to drive the global hemodialysis market growth.

Furthermore, key players are constantly focused on developing new technology in hemodialysis, which is expected to propel the global hemodialysis market growth. For instance, in January 2019, Fresenius Medical Care AG & Co. KGaA, launched a 4008A dialysis machine. The 4008A dialysis machine incorporates high therapy standards and is cost–effective.

Furthermore, in October 2016, Baxter Healthcare Corporation, launched a product HDx with Theranova (dialyzer), a hemodialysis machine used in end–stage renal diseases treatment. According to Baxter Healthcare Corporation, the dialysis machine is very efficient and closely related to natural kidneys of the body in terms of function. It is capable of filtering middle–sized molecules along with smaller molecules effectively. Hence, this factor is expected to accelerate the global hemodialysis market growth.

Global Hemodialysis Market Regional Analysis

North America is expected to dominate the global hemodialysis market over the forecast period. Initiatives taken by the government and other organizations may have a positive impact on the North America hemodialysis market growth. For instance, in April 2019, Baxter International Inc., a medical device company, the National Association for the Advancement of Colored People (NAACP, civil right organization), and the Alliance for Home Dialysis announced to conduct a Dialysis Health Imperative for Access, Choice, and Equity program (ACEP) for the third year. The purpose of this program is to raise awareness about the kidney failure diseases, risk associated with it, treatment options available, etc. Such initiatives may lead to higher adoption of hemodialysis treatment and thereby, is expected to support the global hemodialysis market growth.

Ask For Discount Before Purchasing This Business Report @ http://bit.ly/2Qyla8q

Global Hemodialysis Market Restraints

Side effects of the hemodialysis process may hinder the global hemodialysis market growth. According to National Health Service, U.K., hemodialysis is associated with some side effects, as it is able to compensate partially to the improper kidney function. Certain side effects of hemodialysis such as hypotension, risk of developing sepsis, bone and joint pain, anxiety, insomnia and in some cases erectile dysfunction may occur. Hence, such side effects may lead to lesser adoption of hemodialysis treatment and thereby hindering the global hemodialysis market growth.

Global Hemodialysis Market Key Players

Some of the major players operating in the global hemodialysis market include, Baxter Healthcare Corporation, B. Braun Medical Inc., Fresenius Medical Care AG & Co. KGaA, Toray Industries, Inc., Nikkiso Co. Ltd., JMS Co. Ltd., Diaverum Deutschland GmbH, Nipro Corporation, and Gambro.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Unfractionated Heparin Market New Trends, Market Segmentation, Footprint With Their Financial Condition By 2026

Unfractionated heparin (UFH) is a natural agent widely used to prevent clot formation in vessels. Unfractionated heparin is a fast-acting blood thinner, which works with antithrombin, a natural protein in the body, to block clot formation. UFH is administered to patient intravenously into an arm vein or as a subcutaneous injection under the skin. UFH can also be administrated orally. However, oral absorption of unfractionated heparin is poor, owing to their size and anionic structure. UFH is not absorbed properly from the gastrointestinal tract when taken orally.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1672

Unfractionated heparin is majorly used in deep venous thrombosis (DVT), pulmonary embolism (PE), and venous thromboembolism (VTE) in patients with increased postoperative complications. Unfractionated heparin is the preferred treatment for patients at high risk of bleeding complications, owing to its short activity and reversibility and its reversible anticoagulant effect. Additionally, UTH offers various advantages over other types of heparin, owing to its ability to rapidly enter into the blood stream and less reliant to kidney for extraction. UTH is a preferred anticoagulant option for pregnant women, as it does not cross the placenta, and thus is considered as safe for the fetus.

Unfractionated Heparin Market Drivers

Growth of unfractionated heparin market is increasing, owing to the increasing incidence of thromboembolic disorders such as deep vein thrombosis and pulmonary embolism, and among others. According to the data findings published in the Centers for Disease Control and Prevention (CDC), in February 2018, 900,000 people are affected (1 to 2 per 1,000) each year in the U.S. due to the deep venous thromboembolism and Pulmonary Embolism (DVT/PE). According to data published in the Circulation Research Journal: a journal of the American Heart Association, in 2016, the incidence of venous thromboembolism (VTE) increases with increasing age. According to the same source, in the U.S., study estimated the age-stratified incidence showing 143 per 100000 among ages 40 to 49 years, 200 per 100 000 among ages 50 to 59 years, 391 per 100000 among ages 60 to 69 years, 727 per 100000 among ages 70 to 79 years, and 1134 per 100000 among ages ≥80 years. Additionally, the low awareness regarding the pulmonary embolism and deep-vein thrombosis showing the negligence towards the early diagnosis of these condition. Moreover, healthcare regularity organizations are engaged in increasing the awareness for the same, which will expected to drive the unfractionated heparin market in near future.

Unfractionated Heparin Market - Regional Analysis

On the basis of region, the unfractionated heparin market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds a leading position in the global unfractionated heparin market, owing to increasing prevalence of deep venous thromboembolism and Pulmonary Embolism in the region. For instance, according to the Centers for Disease Control and Prevention (CDC), February 2018 data findings, around 60,000 to 100,000 people are estimated to die due to DVT/PE, in the U.S. Moreover, 10% to 30% of people die within one month from diagnosis. Additionally, according to the same source, around 5% to 8% of the U.S. population has one of several genetic risk factors, such as inherited thrombophilias, which increases the risk for thrombosis.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1672

Unfractionated Heparin Market Competitive Landscape

Some of the key players operating in the unfractionated heparin market are B. Braun Melsungen AG, Pfizer, Inc., Baxter International Inc., Siemens Ag, Sagent Pharmaceuticals, Inc., and LEO Pharma A/S.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Non-Invasive Cancer Diagnostics Market Growing Automation in Healthcare to Benefit Growth of the Market

Non-invasive cancer diagnostics are procedures used for the identification of cancer without incision in the body. Detection and treatment of cancer at early stages are important for long-term survival. Non-invasive cancer detection method is found to be an increasing choice of interest, owing to its painless or minimal pain method of diagnostic coupled with more accurate results. Molecular based diagnostic methods are expected to increase during the forecast period due to launches of new biomarker based detection methods. Moreover, factors like increasing incidence of cancer, increasing cancer screening rate, government initiatives, and emerging technologies such as next generation sequencing are expected to drive the market during the forecast period.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1651

According to Cancer Research UK, currently no diagnostic tests are 100% sensitive in general practice. This suggests the unmet demand for novel diagnostic assay with more efficiency. The efficiency of molecular diagnostics for screening of blood and tissue sample for cancer detection fuels the research and development of biomarker based molecular diagnostic method, which can detect abnormalities in their early developmental cycle. Moreover, according to Genome Biology article published in 2017, the current research in non-invasive cancer detection are targeting two class of studies - the development of biomarkers for a specific cancer type and the characterization of circulating tumor DNA (ctDNA) for general cancer detection, without trying to predict specific cancer types. Such studies will help manufacturers to develop better cancer detection kits for molecular based diagnostics.

Non-Invasive Cancer Diagnostics Market Drivers

Increasing incidence of cancer is expected to be a major factor driving growth of non-invasive cancer diagnostics market. Cancer is a major factor impacting the world economy. For instance, according to the National Cancer Institute (NIH), cancer incidence was 439.2 per 100,000 individuals based on the cancer cases that occurred between 2011 and 2015. The same source estimated that rate of cancer survivors in the U.S. were 15.5 million, which is expected to increase to 20.3 million by 2026.

Increasing rate of cancer detection will also boost the non-invasive cancer diagnostics market growth. According to the U.S. Breast Cancer Surveillance Consortium (BCSC) researchers, the rate of cancer detection increased to 34.7 per 1,000 individuals in 2013, as compared to 25.3 per 1,000 individuals in 2005. Furthermore, governmental and non-governmental organizations are engaged in raising awareness for breast and cervical cancer as well as conducts screening programme. The National Institute for Health and Care Excellence (NICE) is involved in improving diagnosis rate by revising draft guideline for early cancer detection. Moreover, increasing cancer studies for cancer drug development will boost the non-invasive cancer diagnostics market growth. In 2016, NCI's Center to Reduce Cancer Health Disparities launched the National ‘Screen to Save’ Colorectal Cancer Outreach and Screening Initiative. The initiative was aimed at increasing colorectal cancer screening rate.

Non-Invasive Cancer Diagnostics Market - Regional Analysis

On the basis of region, the global non-invasive cancer diagnostics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds a dominant position in the non-invasive diagnostics market, owing to increasing incidence of cancer, increasing technological advancement, better reimbursement scenario, and governmental initiatives for screening of cancer in early stages. For instance, the American Cancer Society Guidelines for the early detection of cancer offers various screening plans at different ages. For example, the guidelines suggest that women between the age of 40 and 44 must screen for breast cancer annually.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1651

Non-Invasive Cancer Diagnostics Market – Competitive Landscape

Some of the key players operating in the global non-invasive cancer diagnostics market include Roche Diagnostics, Hologic Inc., Qiagen, Gen-Probe Inc., Digene Corporation, Abbott Molecular, IVDiagnostics, Laboratory Corporation of America Holdings, OncoCyte Corporation, Arquer Diagnostics Ltd. and Affymetrix Inc.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Medical Tubing Market Procedures Increasing Applications in Healthcare Research and Development

Medical tubing completes a medical industry requirements and standards for various medical or pharmaceutical related applications. Medical tubing is used for fluid management, drainage, anesthesiology and respiratory equipment, intravenous applications (IVs), catheters, peristaltic pumps, and biopharmaceutical laboratory equipment. Medial tubing is equipped with standards and certifications, which represents material and specification requirements for tubes. These standards include Good Manufacturing Practice (GMP) and Current Good Manufacturing Practice (cGMP). Furthermore, Food and Drug Administration (FDA) grants standards depending on specific application required for certain types of medical tubing.

For In depth Information Get Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/1643

Increasing usage of medical tubing in IVs, catheters, peristaltic pumps, and biopharmaceutical laboratory equipment are expected to boost the medical tubing market. For instance, according to Surgical Endoscopy Journal in 2013, surgeons use minimally invasive surgical techniques, primarily laparoscopy and robotic surgery, to perform procedures that were previously done as open surgery. Furthermore, according to the StatPearls Publishing LLC: a peer-reviewed medical article, October 2017; 92% of all cholecystectomies performed in the U.S. are done laparoscopically. Therefore, increasing preference for minimally invasive surgeries is expected to fuel growth of the global medical tubing market during the forecast period.

Market Dynamics

Growing adoption of medical tubing by surgeons for minimally invasive surgeries coupled with rising number of hospital admissions in the intensive care units is also expected to boost the growth of the market. Rising number of patients taking drug delivery through medical tubes, who are unable to take drugs orally, is another factor aiding the growth of medical tubing market.

According to Centers for Disease Control & Prevention (CDC), in 2015, it was estimated that acute injury and chronic obstructive pulmonary diseases (COPD) are major disorders responsible for ICU admissions. According to Biomed Central Respiratory Research, 2016, asthma and chronic obstructive pulmonary disease (COPD) are common chronic obstructive lung disorders characterized by variable airflow limitation and airway hyper responsiveness, affecting over 25 million people in the U.S.

Increasing Prevalence of Chronic Diseases and Life Threatening Diseases is Expected to Augment Market Growth

Increasing prevalence of chronic diseases and life threatening diseases is expected to drastically increase demand for medical tubing devices, which are essentially required during surgery procedures.  For instance, according to a study published by National Center for Biotechnology Information in 2015, it was estimated that around 5.7 million people suffered from heart failure in the U.S. Moreover, according to Centers for Disease Control and Prevention (CDC), 2017, around 610,000 people die of heart disease in the U.S. every year.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1643

According to a report published by the Australian Government, Department of Health in 2017, it was estimated that 1 in every 2 Australians (50%) suffers from at least one type of chronic condition, such as arthritis, asthma, back pain, cancer, cardiovascular disease, chronic obstructive pulmonary disease, diabetes or mental health conditions. Thus, high prevalence of chronic diseases and life threatening diseases is expected to be one of the major factors driving growth of the global medical tubing market.

Some of the key players operating in the medical tubing market are Compagnie de Saint-Gobain S.A., Teleflex Incorporated, Optinova Holding AB, Zeus Industrial Products, Inc., The Lubrizol Corporation, Nordson Corporation, Putnam Plastics Corporation, Raumedic AG, Tekni-Plex, Inc., and Smith Group plc.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Anti-body Coupled T Receptor Therapy Market - Global Industry Insights, Trends, Outlook and Opportunity Analysis 2018-2026

Anti-body coupled T receptor (ACTR) therapy is kind of immunotherapy used to treat cancer in which body’s own immune response is utilized to act on cancerous cell. Anti-body coupled T receptor therapy utilizes T cells from body, engineered it to express specific T cell receptor, multiplying it in lab and then administering it along with targeting antibodies. The advantage in this approach is, that these T cells do not attack normal antigens from blood circulation but attack only antigens attached to the cancerous cells. This is possible as tumor specific monoclonal antibodies are given together with ACTR T cells. ACTR therapy is cost effective as it can be used in various cancer therapy. Also, greater therapeutic benefit with minimum side effects can be possible by adjusting the amount of targeting antibody which is essential for activation of the ACTR T cells.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1600

Rising incidence of cancer and new products to be launched in future to drive the market for anti-body coupled T receptor therapy market.

According to World Health Organization (WHO), cancer is one of the leading non-communicable disease and second leading cause of death globally. As reported by International Agency for Research on Cancer (IARC) in 2012, there were 14.1 million new cases, 8.8 million deaths and 32.6 million people living with cancer worldwide. As per 2017 report by Leukemia and Lymphoma Society, U.S. alone is expected to have prevalence of 8,16,834 and 80,500 annual new cases of lymphoma. Therefore, such high number of cancer patient would propel the anti-body coupled T receptor therapy market.

ACTR therapy is better in its approach than other adoptive T cell transfer technologies such as CAR-T cell therapy. CAR-T therapy products such as Kymriah (Novartis AG) or Yescarta (Gilead Lifescience, Inc.) has side effects such as cytokine release syndrome, and neurological toxicity as discussed in their respective product literatures and other studies. ACTR therapy being specific in its action do not produce such side effects. This advantage would drive the anti-body coupled T receptor therapy market in future. Also CAR-T therapy has application in specific type of cancer such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, multiple myeloma whereas ACTR therapy has potential use even in solid tumorous cancer such as breast cancer, and neuroblastoma.

Cost of product can be a major concern. Kymriah which is a CAR-T therapy costs approximately US$ 4,75,000 per patient. Considering such high cost for CAR-T therapy it can be assumed that anti-body coupled T receptor therapy can also costs on similar line as it works in same segment of immuno oncology, which may limit the potential growth of anti-body coupled T receptor therapy market.

Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/1600

Strategic merger and acquisition amongst the companies to expand the market for anti-body coupled T receptor therapy.

Unum Therapeutics is currently the only company that is working actively in anti-body coupled T receptor therapy. It has several product in its pipeline, and they vary based on the technology used for expression of receptor in patients T cell such as mRNA or viral vector. There is also combination of different monoclonal antibodies to be used for coupling such as rituximab, and trastuzumab. In phase one clinical trial, rituximab coupled t receptor therapy found to produce desired therapeutic effects. Seattle Genetics, Inc. and Unum Therapeutics, Inc. in 2015 entered into a strategic collaboration and license agreement to develop and commercialize novel antibody-coupled T-cell receptor (ACTR) therapies for cancer. This collaboration would enable study of different combination of the tumor-specific monoclonal antibodies with T receptor and cater to patient specific treatment needs.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Bioreactors Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

Bioreactor is an engineered or manufactured vessel that is used in the production of wide range of biological products. Industrial bioreactor is a vessel in which biochemical process is carried out using microbes and animal cells or biologically active compounds that are derived from living cells. Bioreactors are cylindrical in shape with capacity of liters to cubic meters and is the most important component involved in bioprocessing. Fermentation processes such as wine, and beer production are carried out in bioreactors. Bioreactors for large scale production of therapeutic products are made of stainless steel. In biopharmaceutical companies, small glass bioreactors are used for research and development purpose and for scale up activities. Another type of bioreactors are disposable bioreactors, which are meant for single use and hence are called as single-use bioreactors. It is generally used for extensive research and manufacturing. Bioreactors can operate in batch, fed batch, and continuous stirred tank processes. Bioreactors are used to produce therapeutics, which include monoclonal antibodies, vaccines, stem cells, and gene modified cells.

Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/1593

Market Drivers

The efficiency of single-use bioreactors has increased across pharmaceutical industries in terms of production, quality control, and procurement. Single-use bioreactors offer advantages such as consistency in production, increase in speed of manufacturing, reduced operational cost, and reduction in manufacturing time of finished dosage form, which foster growth of bioreactors market. In 2016, as per the National Centre for Biotechnology Information (NCBI), operational cost per gram of monoclonal antibody production (mAb) for single-use bioreactor is around 22% lower than conventional system, mainly due to less labor, utilities, maintenance, and waste. For commercial scale of monoclonal antibody production (mAb), conventional fed-batch bioreactors usually require 10000L – 25000L stainless steel tank to culture cells and produce yield of 2-6 g/L. However, single-use bioreactors employ continuous cell culture supply in 500L - 2000L tank and produces 10 - 30 times higher cell density. Therefore, more quantity of products can be produced by using this single-use bioreactors, with less space and capital cost.  Other factors that contribute to growth of the market include low water usage by single-use systems, less floor space requirement, and low risk of cross contamination in single-use system. Furthermore, in 2016, a case study by Cambridge Healthtech Institute stated that by using single-use (SU) bioreactors, there can be an annual savings of US$ 250,000 in water generation for injections and US$ 60,000 in labor time required to set up and cleaning of stainless steel tank. These factors are expected to drive growth of the bioreactors market over the forecast period.

Market Regional Insights

North America is expected to hold dominant position in bioreactors market due to presence of major biopharmaceutical manufacturing companies. Biopharmaceutical companies such as Gilead Science, Inc., Amgen, and Biogen, Inc. in the U.S. actively conducts research on novel therapies for the treatment of various diseases. Research of therapies associated with oncology such as monoclonal antibodies require usage of bioreactors on small as well as large scale for production purposes. Furthermore, according to the National Centre for Biotechnology Information (NCBI), in 2014, 65.6% of the clinical scale manufacturers and around 42% of the commercial manufacturers used single-use bioreactors to improve their bioprocessing. Europe is expected to witness significant growth rate in the bioreactors market due to increasing usage of bioreactors in biopharmaceutical companies. According to the Organization for Economic Co-operation and Development (OECD), in 2015, around 1,700 biopharmaceutical companies, which utilize bioreactors, are from Europe.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1593

Key players operating in bioreactors market include Thermo Fisher Scientific, Inc., Merck KGaA, GE Healthcare, Pall Corporation, ZETA Holdings GmbH, Sartorius AG BBI, Solaris, Praj HiPurity Systems Limited, BiOENGiNEERiNG, INC., Infors AG, and Appplikon Biotechnology, Inc.

Market Taxonomy

Bioreactors market is segmented on the basis of bioreactor type, usage, capacity, end user, and geography.

By Bioreactor type-

• Stainless Steel Bioreactor
• Glass Bioreactor
• Single-Use Bioreactor

By Usage-

• Large scale production
• Pilot-scale production
• Full scale production

By Capacity-

• 5L – 20L
• 20L - 200L
• 200L – 1500L
• Above 1500L

By End Users-

• Biopharmaceutical companies
• Research Organization
• Others

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com